FGFR2 and cholangiocarcinoma: In a Phase II study conducted in patients with advanced or metastatic CCA with FGFR2 fusions or rearrangements who had failed at least one prior systemic therapy, patients received infigratinib 125 mg once daily in 28-day cycles (3 weeks on, 1 week off) [35,36,37].